2. Natural Products
  3. Disease Research Fields Plants Phenylpropanoids Phenols Microorganisms
  4. Other Diseases other families Simple Phenylpropanols Polyphenols
  5. Caftaric acid

Caftaric acid  (Synonyms: trans-Caftaric acid)

Cat. No.: HY-N0321 Purity: 99.84%
Data Sheet
SDS
COA
Handling Instructions Technical Support

Solubility

In Vivo Dissolution Calculator

Caftaric acid (trans-Caftaric acid) is a polyphenolic antidiuretic, antioxidant and anti-apoptotic agent that can be hydrolyzed by intestinal microbial esterases. Caftaric acid exerts its antioxidant and potential anti-inflammatory effects mainly through intestinal microbial metabolism. Caftaric acid can reduce renal damage, restore electrolyte balance, renal function indicators and antioxidant enzyme activities in a rat albinism model, and further exert anti-oxidative stress and anti-inflammatory activities.

For research use only. We do not sell to patients.

Caftaric acid Chemical Structure

Caftaric acid Chemical Structure

CAS No. : 67879-58-7

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 84 In-stock
Solution
10 mM * 1 mL in DMSO USD 88 In-stock
Solid
5 mg USD 80 In-stock
10 mg USD 125 In-stock
50 mg USD 400 In-stock
100 mg   Get quote  
200 mg   Get quote  

Get it by April 22 for select sizes. Order within 15 hrs 1 mins.

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Caftaric acid:

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Caftaric acid (trans-Caftaric acid) is a polyphenolic antidiuretic, antioxidant and anti-apoptotic agent that can be hydrolyzed by intestinal microbial esterases. Caftaric acid exerts its antioxidant and potential anti-inflammatory effects mainly through intestinal microbial metabolism. Caftaric acid can reduce renal damage, restore electrolyte balance, renal function indicators and antioxidant enzyme activities in a rat albinism model, and further exert anti-oxidative stress and anti-inflammatory activities[1][2][3].

In Vitro

In an in vitro human fecal microbial fermentation experiment, Caftaric acid (1 μmol; 2 h) is rapidly metabolized, and no free caffeic acid or tartaric acid was detected. The main metabolites were 3-hydroxyphenylpropionic acid (3-HPP) and benzoic acid (BA). 3-HPP reached a peak value (0.24 μmol) at 2 hours[1].
In the same experiment, Caftaric acid (1 μmol; 24 h) produces benzoic acid (BA) continuously, accounting for 4-5% of the initial dose at 24 hours[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo

Caftaric acid (40, 80 mg/kg; ip; once daily; 2 weeks) alleviates renal injury in the lead acetate-induced nephrotoxicity model in male albino Sprague Dawley rats through antidiuretic, antioxidant and antiapoptotic activities, restores electrolyte balance, renal function indicators and antioxidant enzyme activities, and improves histopathological changes[2].
Caftaric acid (80 mg/kg; ip; once daily; 2 weeks) does not cause obvious renal injury or electrolyte disturbances in normal male albino Sprague Dawley rats[2].
Caftaric acid (40, 80 mg/kg; ip; once before reperfusion) alleviates renal and lung tissue damage in the Wistar rat renal ischemia-reperfusion model by reducing oxidative stress (MDA, MPO, TOS, OSI), inhibiting apoptosis (caspase-3), autophagy (LC3) and inflammation (COX-2)[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male albino Sprague Dawley rats (120-130 g, male, 120-130 g) with lead acetate-induced nephrotoxicity[2]
Dosage: 40 mg/kg, 80 mg/kg
Administration: Intraperitoneal injection, daily for 2 weeks.
Result: Caused significant decreases in kidney weight, serum electrolytes (sodium, potassium, chloride), antioxidant enzymes (SOD, GPx, GSH), and p53 expression, along with increases in urinary volume, renal function markers (urea, creatinine, uric acid), lipid peroxidation (MDA), and bcl-2 expression.
Co-administration dose-dependently reversed these changes, restoring electrolyte balance, renal function, antioxidant capacity, and apoptotic markers, and improving histopathological lesions (reduced necrosis, vacuolar degeneration, and cast formation in renal tubules).
Animal Model: Normal male albino Sprague Dawley rats (120-130 g, male, 120-130 g)[2]
Dosage: 80 mg/kg
Administration: Intraperitoneal injection, daily for 2 weeks.
Result: Treatment alone had no significant effect on body weight, food/water intake, serum electrolytes, renal function markers (urea, creatinine, uric acid), kidney weight, or antioxidant/oxidative stress parameters (SOD, GPx, GSH, MDA) compared to the control group.
Animal Model: Wistar rats (210±10 g) with renal ischemia-reperfusion injury (1 h renal artery occlusion, 24 h reperfusion)[3]
Dosage: 40 mg/kg, 80 mg/kg
Administration: Intraperitoneal injection, once 30 min before reperfusion.
Result: In the ischemia-reperfusion group, increased oxidant parameters (MDA, MPO, TOS, OSI), while decreased antioxidant parameters (SOD, TAS).
Severe immunopositivity for caspase-3 (apoptosis), LC3 (autophagy), and COX-2 (inflammation) in renal and lung tissues, with histopathological changes including renal necrosis, hyalinization, and lung hyperplasia.
Reduced oxidant levels, enhanced antioxidant capacity, diminished immunopositivity for caspase-3, LC3, and COX-2, and improved histopathological lesions in a dose-dependent manner, with the high dose (80 mg/kg) showing more pronounced effects.
Molecular Weight

312.23

Formula

C13H12O9
CAS No.
Appearance

Solid

Color

Off-white to yellow

SMILES

O=C(O)[C@H](OC(/C=C/C1=CC=C(O)C(O)=C1)=O)[C@@H](O)C(O)=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

H2O : 50 mg/mL (160.14 mM; Need ultrasonic)

DMSO : 50 mg/mL (160.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.2028 mL 16.0138 mL 32.0277 mL
5 mM 0.6406 mL 3.2028 mL 6.4055 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (8.01 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (8.01 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 25 mg/mL (80.07 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Purity & Documentation

Purity: 99.84%

Data Sheet (279 KB) SDS (393 KB)

COA (247 KB) HNMR (678 KB) RP-HPLC (74 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 3.2028 mL 16.0138 mL 32.0277 mL 80.0692 mL
5 mM 0.6406 mL 3.2028 mL 6.4055 mL 16.0138 mL
10 mM 0.3203 mL 1.6014 mL 3.2028 mL 8.0069 mL
15 mM 0.2135 mL 1.0676 mL 2.1352 mL 5.3379 mL
20 mM 0.1601 mL 0.8007 mL 1.6014 mL 4.0035 mL
25 mM 0.1281 mL 0.6406 mL 1.2811 mL 3.2028 mL
30 mM 0.1068 mL 0.5338 mL 1.0676 mL 2.6690 mL
40 mM 0.0801 mL 0.4003 mL 0.8007 mL 2.0017 mL
50 mM 0.0641 mL 0.3203 mL 0.6406 mL 1.6014 mL
60 mM 0.0534 mL 0.2669 mL 0.5338 mL 1.3345 mL
80 mM 0.0400 mL 0.2002 mL 0.4003 mL 1.0009 mL
100 mM 0.0320 mL 0.1601 mL 0.3203 mL 0.8007 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Caftaric acid Related Classifications

Keywords:

Caftaric acid67879-58-7trans-Caftaric acidOthersInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Caftaric acid
Cat. No.:
HY-N0321
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.